Different perspectives and educational resources

Educational resources about unmet needs in later lines of CML

Patient Stories

When thinking of CML, some may think of early-line success
Hear from patients living with later lines of CML

Expert Perspectives

CML Expert Perspectives podcast series

 
Image showing Dr Carla Boquimpani Dr Carla Boquimpani (Brazil) discusses CML in later lines and her goals for patients
 
00:00
 
 
00:00
 
 
 
Image showing Dr Fabio Stagno Dr Fabio Stagno (Italy) on intolerance and resistance in later lines of CML
 
00:00
 
 
00:00
 
 
 
Image showing Dr Eri Matsuki Dr Eri Matsuki's (Japan) view on when it may be appropriate to switch CML treatments
 
00:00
 
 
00:00
 
 
 
Image showing Dr Fabian Lang Dr Fabian Lang's (Germany) point of view on unmet needs in CML
 
00:00
 
 
00:00
 
 
 
The views and opinions expressed in these podcasts are solely those of the speakers. These podcasts are not intended to and do not serve as medical advice, guidance, or recommendations from Novartis Pharmaceuticals Corporation.

Additional Resources

Unmet need

  • Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114(10):2168-2171.
  • Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116(25):5497-5500.

Off-target activities

  • Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-336.
  • Karaman MW, Herrgard H, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-132.
  • Huang D, Zhou T, Lafleur K, Nevado C, et al. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics. 2010;26(2):198-204.

Mechanism of action

  • Fallacara AL, Tintori C, Radi M, et al. Insight into the allosteric inhibition of Abl kinase. J Chem Inf Model. 2014;54(5):1325-1338.

CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

This site is for US health care professionals only.

Use of website is governed by the Terms of Use and Privacy Policy

Copyright © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.

 

9/21 152562